Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RenovoRx, Inc.RNXT · Entity 6797 | Chief Clinical Officer | April 03, 2026 | April 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RenovoRx, Inc.
Report date April 03, 2026 · Filed April 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.98 | Direct | 128,550 |
Reported balance
After 2026-04-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-03 · Grant · Acquired 128,550 · Balance 128,550 F1: On April 3, 2026, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 128,550 shares of the Issuer's common stock (66,954 shares of which are underlying incentive stock options and 61,596 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2026. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2030, and will expire on April 3, 2036. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 3, 2026, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 128,550 shares of the Issuer's common stock (66,954 shares of which are underlying incentive stock options and 61,596 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2026. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2030, and will expire on April 3, 2036.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 03, 2026 Filed Apr 8, 2026 00:00 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Option · Derivative | 128,550 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001493152-26-015592 · ownership.xml · derivative · entry 1 Gentry Leesa · CIK 0002013097 · Chief Clinical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,550 Underlying: Common Stock · 128,550 shares Expires not disclosed F1 · derivative.exercise_date: On April 3, 2026, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 128,550 shares of the Issuer's common stock (66,954 shares of which are underlying incentive stock options and 61,596 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2026. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2030, and will expire on April 3, 2036. F1 · derivative.expiration_date: On April 3, 2026, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 128,550 shares of the Issuer's common stock (66,954 shares of which are underlying incentive stock options and 61,596 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2026. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2030, and will expire on April 3, 2036. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 20:45 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Option · Derivative | 6,619 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001641172-25-017831 · ownership.xml · derivative · entry 1 Gentry Leesa · CIK 0002013097 · Chief Clinical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,619 Underlying: Common Stock · 6,619 shares Expires not disclosed F1 · shares: Represents an award of 2,621 incentive stock options and 3,998 non-qualified options under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan (the "Plan") to the Reporting Person, which award was approved by the Compensation Committee of the Issuer's Board of Directors on July 1, 2025. Such award represents a number of options previously allocated to the Reporting Person for services rendered, the issuance of which was contingent upon the availability of shares under the Plan. Such availability became effective upon stockholder approval of an increase in the shares reserve at the Issuer's annual meeting of stockholders held on June 24, 2025. F2 · derivative.exercise_date: The options vest over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on July 1, 2035. F2 · derivative.expiration_date: The options vest over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The option will only become exercisable when there is an effective registration statement covering the shares underlying the option. The option will become fully vested on January 1, 2029, and will expire on July 1, 2035. F1 · derivative.underlying_shares: Represents an award of 2,621 incentive stock options and 3,998 non-qualified options under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan (the "Plan") to the Reporting Person, which award was approved by the Compensation Committee of the Issuer's Board of Directors on July 1, 2025. Such award represents a number of options previously allocated to the Reporting Person for services rendered, the issuance of which was contingent upon the availability of shares under the Plan. Such availability became effective upon stockholder approval of an increase in the shares reserve at the Issuer's annual meeting of stockholders held on June 24, 2025. Read SEC document |
| April 14, 2025 Filed Apr 16, 2025 21:18 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Option · Derivative | 26,477 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001641172-25-005108 · ownership.xml · derivative · entry 1 Gentry Leesa · CIK 0002013097 · Chief Clinical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,477 Underlying: Common Stock · 26,477 shares Expires not disclosed F1 · derivative.exercise_date: On April 14, 2025, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 26,477 shares of the Issuer's common stock (7,173 shares of which are underlying incentive stock options and 19,304 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2029, and will expire on April 14, 2035. F1 · derivative.expiration_date: On April 14, 2025, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 26,477 shares of the Issuer's common stock (7,173 shares of which are underlying incentive stock options and 19,304 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2029, and will expire on April 14, 2035. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:28 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantOptions · Derivative | 190,000 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0001493152-24-009409 · ownership.xml · derivative · entry 1 Gentry Leesa · CIK 0002013097 · Chief Clinical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires not disclosed F1 · price: Represents 10-year incentive stock options to purchase 190,000 shares of the Company's common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. These options vest over four years at a rate of 1/48 per month, beginning to vest on March 1, 2024. F1 · derivative.exercise_date: Represents 10-year incentive stock options to purchase 190,000 shares of the Company's common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. These options vest over four years at a rate of 1/48 per month, beginning to vest on March 1, 2024. F1 · derivative.expiration_date: Represents 10-year incentive stock options to purchase 190,000 shares of the Company's common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. These options vest over four years at a rate of 1/48 per month, beginning to vest on March 1, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.